Description
The 17C9 monoclonal antibody specifically recognizes Complement receptor of the immunoglobulin superfamily (CRIg) which is encoded by the Vsig4 (V-set and immunoglobulin domain containing 4) gene. CRIg is a ~45 kDa single-pass type I transmembrane glycoprotein that contains a variable (V-type) immunoglobulin domain in its extracellular region which is required for binding complement components and promoting phagocytosis. CRIg is expressed on Kupffer cells and tissue resident macrophages, including a subset of resident peritoneal macrophages. CRIg binds complement fragments C3b and iC3b and plays important roles in innate and adaptive immunity. This complement receptor is involved in regulation of the complement cascade and serves as a phagocytic receptor in the clearance of pathogens, immune complexes, and apoptotic cells. CRIg-positive macrophages can reportedly function in the negative regulation of T-cell proliferation and IL-2 production.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
5. An isotype control should be used at the same concentration as the antibody of interest.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
8. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
9. Researchers should determine the optimal concentration of this reagent for their individual applications.
